{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:41:18Z","timestamp":1793385678146,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT108082AIA"],"award-info":[{"award-number":["WT108082AIA"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Real-world\u00a0data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using binding antibodies analysis coupled with pseudotyped virus neutralisation assays in two cohorts from West Africa: Nigerian healthcare workers (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009140) and a Ghanaian community cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009527) pre and post vaccination. We found 44 and 28% of pre-vaccination participants showed IgG anti-N positivity, increasing to 59 and 39% respectively with anti-receptor binding domain (RBD) IgG-specific antibodies. Previous IgG anti-N positivity significantly increased post two-dose neutralizing antibody titres in both populations. Serological evidence of breakthrough infection was observed in 8\/49 (16%). Neutralising antibodies were observed to wane in both populations, especially in anti-N negative participants with an observed waning rate of 20% highlighting the need for a combination of additional markers to characterise previous infection. We conclude that AZD1222 is immunogenic in two independent West African cohorts with high background seroprevalence and incidence of breakthrough infection in 2021. Waning titres post second dose indicates the need for booster dosing after AZD1222 in the African setting despite hybrid immunity from previous infection.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-33792-x","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T08:08:14Z","timestamp":1665994094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa"],"prefix":"10.1038","volume":"13","author":[{"given":"Adam","family":"Abdullahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oladele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-150X","authenticated-orcid":false,"given":"Michael","family":"Owusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-6793","authenticated-orcid":false,"given":"Steven A.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ayorinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abideen","family":"Salako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehintola","family":"Ige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A. T. M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-914X","authenticated-orcid":false,"given":"Augustina Angelina","family":"Sylverken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Onwuamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame Ofori","family":"Boadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazeem","family":"Osuolale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-9159","authenticated-orcid":false,"given":"James Opoku","family":"Frimpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufai","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-0531","authenticated-orcid":false,"given":"Azuka","family":"Okuruawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna Wisso","family":"Abdullahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Liboro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence Duah","family":"Agyemang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0961-4434","authenticated-orcid":false,"given":"Nana Kwame","family":"Ayisi-Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatosin","family":"Odubela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Ohihoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ezechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-555X","authenticated-orcid":false,"given":"Japhet Senyo","family":"Kamasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ameyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-784X","authenticated-orcid":false,"given":"Joshua","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8941-0748","authenticated-orcid":false,"given":"Derrick Boakye","family":"Kyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-5870","authenticated-orcid":false,"given":"Dorcas Ohui","family":"Owusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-3009","authenticated-orcid":false,"given":"Olagoke","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunday","family":"Mogaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedamola","family":"Dada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Agyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes Ceron","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-2940","authenticated-orcid":false,"given":"Sani H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Doffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-5219","authenticated-orcid":false,"given":"Rosemary","family":"Audu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Adegbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6908-9363","authenticated-orcid":false,"given":"Petra","family":"Mlcochova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Odame","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde Lawal","family":"Solako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-1808","authenticated-orcid":false,"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"33792_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"33792_CR2","doi-asserted-by":"publisher","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature https:\/\/doi.org\/10.1038\/s41586-022-04474-x (2022).","DOI":"10.1038\/s41586-022-04474-x"},{"key":"33792_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114\u2013119 (2021).","journal-title":"Nature"},{"key":"33792_CR4","doi-asserted-by":"publisher","first-page":"109292","DOI":"10.1016\/j.celrep.2021.109292","volume":"35","author":"B Meng","year":"2021","unstructured":"Meng, B. et al. Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 35, 109292 (2021).","journal-title":"Cell Rep."},{"key":"33792_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/infdis\/jiab368","volume":"224","author":"I Ferreira","year":"2021","unstructured":"Ferreira, I. et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J. Infect. Dis. 224, 989\u2013994 (2021).","journal-title":"J. Infect. Dis."},{"key":"33792_CR6","doi-asserted-by":"publisher","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv https:\/\/doi.org\/10.1101\/2021.01.26.21250224 (2021).","DOI":"10.1101\/2021.01.26.21250224"},{"key":"33792_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234\u2013236 (2022).","journal-title":"Lancet"},{"key":"33792_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"key":"33792_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","volume":"593","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136\u2013141 (2021).","journal-title":"Nature"},{"key":"33792_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJMc2202542","volume":"386","author":"G Regev-Yochay","year":"2022","unstructured":"Regev-Yochay, G. et al. Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron. N. Engl. J. Med. 386, 1377\u20131380 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33792_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"33792_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(21)01462-8","volume":"398","author":"EC Wall","year":"2021","unstructured":"Wall, E. C. et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet 398, 207\u2013209 (2021).","journal-title":"Lancet"},{"key":"33792_CR13","doi-asserted-by":"publisher","first-page":"797589","DOI":"10.3389\/fimmu.2022.797589","volume":"13","author":"T Tada","year":"2022","unstructured":"Tada, T. et al. Neutralization of SARS-CoV-2 variants by mRNA and adenoviral vector vaccine-elicited antibodies. Front Immunol. 13, 797589 (2022).","journal-title":"Front Immunol."},{"key":"33792_CR14","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021).","journal-title":"BMJ"},{"key":"33792_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","volume":"399","author":"LG Bekker","year":"2022","unstructured":"Bekker, L. G. et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet 399, 1141\u20131153 (2022).","journal-title":"Lancet"},{"key":"33792_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med"},{"key":"33792_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422 (2021).","journal-title":"Nature"},{"key":"33792_CR18","doi-asserted-by":"publisher","unstructured":"Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G spike variant. Cell. Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100099 (2020).","DOI":"10.1016\/j.xcrm.2020.100099"},{"key":"33792_CR19","doi-asserted-by":"publisher","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2102214 (2021).","DOI":"10.1056\/NEJMoa2102214"},{"key":"33792_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02342-z","volume":"20","author":"MG Chibwana","year":"2022","unstructured":"Chibwana, M. G. et al. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med 20, 128 (2022).","journal-title":"BMC Med"},{"key":"33792_CR21","doi-asserted-by":"publisher","unstructured":"Collaborators, C.-C. I. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(22)00484-6 (2022).","DOI":"10.1016\/S0140-6736(22)00484-6"},{"key":"33792_CR22","doi-asserted-by":"publisher","unstructured":"Muecksch, F. et al. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity. MedRxiv https:\/\/doi.org\/10.1101\/2021.07.02.21259939 (2021).","DOI":"10.1101\/2021.07.02.21259939"},{"key":"33792_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1126\/science.abj9932","volume":"374","author":"MS Dhar","year":"2021","unstructured":"Dhar, M. S. et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science 374, 995\u2013999 (2021).","journal-title":"Science"},{"key":"33792_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07094-y","volume":"22","author":"CA Prete Jr.","year":"2022","unstructured":"Prete, C. A. Jr. et al. Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil. BMC Infect. Dis. 22, 127 (2022).","journal-title":"BMC Infect. Dis."},{"key":"33792_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4269\/ajtmh.21-0718","volume":"107","author":"SK Ofori","year":"2022","unstructured":"Ofori, S. K. et al. Transmission dynamics of COVID-19 in Ghana and the impact of public health interventions. Am. J. Trop. Med Hyg. 107, 175 (2022).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"33792_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42269-022-00729-9","volume":"46","author":"ED Jacobs","year":"2022","unstructured":"Jacobs, E. D. & Okeke, M. I. A critical evaluation of Nigeria\u2019s response to the first wave of COVID-19. Bull. Natl. Res. Cent. 46, 1\u20139 (2022).","journal-title":"Bull. Natl. Res. Cent."},{"key":"33792_CR27","unstructured":"Dan-Nwafor, C. et al. Nigeria\u2019s public health response to the COVID-19 pandemic: January\u2013May 2020. J. Global Health https:\/\/doi. 10.7189\/jogh.10.020399 (2020)."},{"key":"33792_CR28","doi-asserted-by":"publisher","first-page":"e004793","DOI":"10.1136\/bmjgh-2020-004793","volume":"6","author":"I Abubakar","year":"2021","unstructured":"Abubakar, I., Dalglish, S. L., Ihekweazu, C. A., Bolu, O. & Aliyu, S. H. Lessons from co-production of evidence and policy in Nigeria\u2019s COVID-19 response. BMJ Glob. Health 6, e004793 (2021).","journal-title":"BMJ Glob. Health"},{"key":"33792_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1126\/science.abm0811","volume":"375","author":"CJ Reynolds","year":"2022","unstructured":"Reynolds, C. J. et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science 375, 183\u2013192 (2022).","journal-title":"Science"},{"key":"33792_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","volume":"397","author":"C Manisty","year":"2021","unstructured":"Manisty, C. et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 397, 1057\u20131058 (2021).","journal-title":"Lancet"},{"key":"33792_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","volume":"29","author":"R Keeton","year":"2021","unstructured":"Keeton, R. et al. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host Microbe 29, 1611\u20131619 e1615 (2021).","journal-title":"Cell Host Microbe"},{"key":"33792_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30219-5","volume":"13","author":"CM Morang\u2019a","year":"2022","unstructured":"Morang\u2019a, C. M. et al. Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. Nat. Commun. 13, 2494 (2022).","journal-title":"Nat. Commun."},{"key":"33792_CR33","doi-asserted-by":"publisher","unstructured":"Weidenbacher, P. A.-B. et al. Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade. bioRxiv https:\/\/doi.org\/10.1038\/s41589-022-01140-1 (2022).","DOI":"10.1038\/s41589-022-01140-1"},{"key":"33792_CR34","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","volume":"30","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe 30, 880\u2013886.e884 (2022).","journal-title":"Cell Host Microbe"},{"key":"33792_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"33792_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2478\/jccm-2021-0018","volume":"7","author":"HE Baxendale","year":"2021","unstructured":"Baxendale, H. E. et al. Critical care workers have lower seroprevalence of SARS-CoV-2 IgG compared with non-patient facing staff in first wave of COVID19. J. Crit. Care Med. 7, 199\u2013210 (2021).","journal-title":"J. Crit. Care Med."},{"key":"33792_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33792_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14411-7","volume":"12","author":"SA Kemp","year":"2022","unstructured":"Kemp, S. A. et al. Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. Sci. Rep. 12, 10492 (2022).","journal-title":"Sci. Rep."},{"key":"33792_CR39","doi-asserted-by":"publisher","unstructured":"Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA Boost. Nature https:\/\/doi.org\/10.1038\/s41586-022-04778-y (2022).","DOI":"10.1038\/s41586-022-04778-y"},{"key":"33792_CR40","doi-asserted-by":"publisher","unstructured":"Arbel, R. et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60\u2009years. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01832-0 (2022).","DOI":"10.1038\/s41591-022-01832-0"},{"key":"33792_CR41","doi-asserted-by":"publisher","unstructured":"Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature https:\/\/doi.org\/10.1038\/s41586-022-04462-1 (2022).","DOI":"10.1038\/s41586-022-04462-1"},{"key":"33792_CR42","doi-asserted-by":"publisher","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature https:\/\/doi.org\/10.1038\/s41586-022-04411-y (2022).","DOI":"10.1038\/s41586-022-04411-y"},{"key":"33792_CR43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"X Xiong","year":"2020","unstructured":"Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934\u2013941 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"33792_CR44","doi-asserted-by":"publisher","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. bioRxiv https:\/\/doi.org\/10.1101\/2020.06.08.140871 (2020).","DOI":"10.1101\/2020.06.08.140871"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33792-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T20:02:37Z","timestamp":1666036957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33792-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33792"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33792-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.04.22274668","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1834968\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K.G has received honoraria for educational activities from Janssen, Moderna, and GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of NIMR (IRB-21-040) and the Committee of Human Research, Publication and Ethics of KNUST (CHRPE\/AP\/091\/21). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6131"}}